Companion Diagnostics Market Size to Hit USD 9.3 Billion Revenue by 2028 with 9% CAGR: Report by Transparency Market Research
20 août 2024 10h38 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc., Aug. 20, 2024 (GLOBE NEWSWIRE) -- The global companion diagnostics market (동반진단 시장) was worth US$ 5.2 Bn in 2020 and is...
Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
12 août 2024 08h30 HE
|
Atossa Therapeutics, Inc.
Presented data showing 100% disease control rate after 24-week treatment with (Z)-Endoxifen in 40mg cohort of Phase 2 EVANGELINE study at the American Association for Cancer Research (AACR) Annual...
Elucent Medical Announces Froedtert & the Medical College of Wisconsin Health Network to Provide New Breast Cancer Surgical Technology
09 août 2024 08h00 HE
|
Elucent
EDEN PRAIRIE, Minn., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Elucent Medical, a pioneering medical technology company transforming the field of guided surgical technology, is thrilled to announce...
Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
06 août 2024 16h02 HE
|
Olema Oncology
Presented promising interim clinical results from the ongoing study of palazestrant in combination with ribociclib at the 2024 ESMO Breast Cancer Congress. Updated results expected to be presented at...
Processa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast Cancer
30 juil. 2024 08h00 HE
|
Processa Pharmaceuticals, Inc.
Open-label Phase 2 trial in breast cancer to begin this quarter Initial data expected mid-2025 HANOVER, Md., July 30, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA)...
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
30 juil. 2024 07h00 HE
|
Arvinas Inc.
– Completed enrollment in the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting; continued enrollment globally in multiple clinical trials of vepdegestrant in ER+/HER2-...
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
29 juil. 2024 09h15 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., July 29, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s...
Shuttle Pharma’s Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE
19 juil. 2024 09h00 HE
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., July 19, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company...
Sermonix Pharmaceuticals Receives U.S. Patent for Lasofoxifene as Method for Treating Aromatase-Resistant ER+ Breast Cancer in the Absence of ESR1 Mutations
18 juil. 2024 09h00 HE
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, July 18, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...
What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk
17 juil. 2024 08h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, July 17, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced results from its nationwide Cancer Risk...